Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Regenerons $0.33 Billion Trading Day 287th in Activity as Sepsis Trial Advances and Eylea HD Approval Drive Mixed Investor Signals – AInvest
Regenerons $0.33 Billion Trading Day 287th in Activity as Sepsis Trial Advances and Eylea HD Approval Drive Mixed Investor Signals AInvest Source: Author: | Date: 2025-08-29 23:47:00 Source: Author: | Date: 2025-08-29 23:47:00
A study of the progression of sensitivity loss in GA over time using inferred data
(Image Credit: AdobeStock) The recent OMEGA study1 found that “inferred sensitivity” mapping may be a potential functional surrogate end point for geographic atrophy (GA) based on its ability to predict retinal function with high spatial resolution and without extensive psychophysical…
FDA issues complete response letter to Outlook Therapeutics for resubmitted BLA for ONS-5010
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Outlook Therapeutics’ biologics license application (BLA) resubmission for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (AMD). The recent CRL included only 1 deficiency, for…
Study finds value in home OCT monitoring
(Image credit: AdobeStock/Pixel-Shot) A study published in Ophthalmology Science shows that by analyzing up-to daily home OCT images, artificial intelligence (AI) can accurately track disease activity in patients with wet age-related macular degeneration (AMD). This may allow physicians to manage…
Michael X. Repka, MD, MBA, on building consensus and future directions
In advance of the upcoming CCOI Myopia Workshop, scheduled for September 8 in Paris, France, Michael X. Repka, MD, MBA—program co-chair of the event and current president of the American Academy of Ophthalmology—spoke about the challenges and opportunities facing the…
First patient dosed in Qlaris Bio’s phase 2 Nightingale clinical trial for QLS-111
(Image Credit: AdobeStock) The first patient has been dosed in Qlaris Bio’s Phase II Nightingale clinical trial for QLS-111 in patients with normal tension glaucoma (NTG).1 The study, which is Qlaris Bio’s third phase 2 clinical trial of the company’s…
OCT changes with low-level red light therapy for myopia in children
(Image credit: AdobeStock/Microgen) Zhehuan Zhang, MD, and colleagues from the Department of Ophthalmology, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, emphasized the importance of patients undergoing routine optical coherence tomography (OCT) scans during repeated low-level red-light (RLRL)…
Aflibercept 8 mg Shows Long-Term Efficacy in Diabetic Macular Edema with Fewer Injections, shows trial – Medical Dialogues
Aflibercept 8 mg Shows Long-Term Efficacy in Diabetic Macular Edema with Fewer Injections, shows trial Medical Dialogues Source: Author: | Date: 2025-08-26 15:00:00 Source: Author: | Date: 2025-08-26 15:00:00
The potential of AI in retina with Daniela Ferrara
This conversation features Daniella Ferrara, Chief Medical Officer for TopCon Healthcare, discussing the transformative potential of artificial intelligence in retinal imaging and ophthalmology. Ferrara, an ophthalmologist and retina specialist with 25 years of experience in retinal imaging innovation. The discussion…
Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
(Image Credit: AdobeStock/Naypong Studio) Nicox has announced that the phase 3 Denali trial of NCX 470 0.1% met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline in open-angle glaucoma or ocular hypertension patients compared to the…